UCB sells to Adams Respiratory Therapeutics Delsym cough surpressants


UCB S.A. announces that it has reached an agreement with Adams Respiratory Therapeutics Inc. to sell Delsym® (dextromethorphan polistirex), an over-the-counter (OTC) 12-hour liquid cough suppressant. In addition, the two companies have entered into a separate agreement for the licensing of the 12-hour liquid technology.

The financial terms of the agreement consist of a one-time, upfront payment to UCB of 122 million U.S. dollars, royalties for a period of 5 years based on sales and a standard manufacturing supply agreement with a "cost-plus" structure.

Other news from the department business & finance

Most read news

More news from our other portals